Select Language

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag & Avi Tag (1)His Tag (1)
Conjugate
Biotin-labeled (1)PE Labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HLE-H82E5	Human	HEK293	Biotinylated Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Complex Protein (Monomer, MALS verified)
HLE-HP2H4	Human	HEK293	PE-Labeled Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Tetramer Protein

Total: 2

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) Background

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*1101 EBV (AVFDRKSDAK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M and AVFDRKSDAK peptide of the EBV.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indication	Clinical Trial
Lifitegrast	SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606	Approved	Shire Development Llc	Xiidra	United States	Dry Eye Syndromes	Bausch And Lomb Inc	2016-07-11	Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia	Details